Table 4.

COMPARE analysis results for compounds 4d and 4f.

Compound	End point	PCCa	Target	Target vector NSC	Target mechanism of actionb
4d	GI50	0.651	Brequinar	S368390	Dihydroorotate dehydrogenase inhibitor
		0.634	Dichloroallyl lawsone	S126771	DNA/RNA antimetabolite
		0.626	Trimetrexate	S352122	Dihydrofolate reductase inhibitor
		0.62	l-Cysteine analog	S303861	Reversible binding inhibitor of the human kinesin Eg5, antimitotic agent
		0.586	Soluble Baker's Antifol	S139105	RNA/DNA antimetabolite
		0.568	Glycoxalic acid	S267213
4f	GI50	0.636	Maytansine	S153858	RNA/DNA antimetabolite
		0.573	Rhizoxin	S749069	Microtubule polymerization inhibitor
		0.550	Macbecin II	S269148	DNA antimetabolite

^aOnly correlations with PCC ≥ 0.55 were selected, as significant.

^bPutative mechanisms of action were identified with the use of literature sources.